AgeX Therapeutics Inc. (AGE) and LyGenesis Terminate Merger Negotiations

July 23, 2021 4:15 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was in the best interest of their respective shareholders not to proceed with the merger given the diversity of the companies’ technology platforms and product development focus.

AgeX will continue to consider new strategic opportunities as they arise. AgeX remains committed to creating shareholder value through third-party collaborations and licensing agreements for its core technologies UniverCyte™ and PureStem®, and its cell therapy programs, including AGEX-VASC1 and AGEX-BAT1. AgeX also will continue to explore financing for its iTR™ technology.

LyGenesis will continue to advance its clinical-stage allogeneic cell therapy for patients with end stage liver disease, and advance its pipeline of preclinical cell therapies enabling pancreas, thymus, and kidney regeneration.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Mergers and Acquisitions

Related Entities

Twitter, Definitive Agreement